Table 6.
Demographics of national COV-AD cohort (n = 525)
| Age (yr, median, IQR) |
58.0 (43.0–69.0) |
| Sex (n, %M) | 221 (42.1%) |
| Diagnosis (n,%) | |
| Primary immunodeficiencies | |
|
- Common variable immunodeficiency - Other primary antibody deficiency - Specific polysaccharide antibody deficiency - Combined immunodeficiency - X-linked agammaglobulinemia - Other |
233 (44.4%) 69 (13.1%) 26 (4.9%) 23 (4.4%) 21 (4.0%) 14 (2.7%) |
| Secondary immunodeficiencies | |
| - Secondary immunodeficiency | 139 (26.5%) |
| Immunoglobulin replacement (n,%) | |
|
- Intravenous - Subcutaneous - None - No data |
256 (48.8%) 234 (44.5%) 34 (6.5%) 1 (0.2%) |
|
Pre treatment IgG (g/L, median, IQR) |
3.2 (1.55–4.50) |
|
Immunoglobulin replacement dose (g/kg/m, median, IQR) |
0.56 (0.47–0.70) |
|
Trough IgG (g/L, median, IQR) |
9.4 (8.1–11.0) |
| Prophylactic antibiotics (n, %) | 273 (52.0%) |